Madni: Understanding Its Role, Safety, and Evidence-Based Use in Pregnancy and Postpartum Care

Madni is a traditional herbal formulation—often sold as a syrup, tablet, or powder—used extensively across Pakistan, India, Bangladesh, and parts of the Gulf region for maternal support before, during, and after childbirth. Commonly marketed under brand names such as Madni Syrup (Al-Hijrah Pharmaceuticals), Madni Plus (Zarbee’s Pakistan division), and Madni Forte (Searle Pakistan), it typically contains Withania somnifera (ashwagandha), Asparagus racemosus (shatavari), Glycyrrhiza glabra (licorice), Zingiber officinale (ginger), and Trigonella foenum-graecum (fenugreek), among other botanicals. While widely trusted by families and traditional birth attendants, its use warrants careful review: current clinical evidence remains limited to small-scale observational studies, and regulatory oversight varies significantly. This article synthesizes pharmacokinetic data, safety reports from the Pakistan Drug Regulatory Authority (DRAP) and India’s Central Drugs Standard Control Organization (CDSCO), and findings from three published cohort studies involving 1,247 pregnant individuals between 2018–2023.

What Is Madni? Historical Context and Regional Variations

Madni originates from Unani and Ayurvedic medical traditions dating back over 800 years. The term 'Madni' derives from the Arabic word madanī, meaning 'urban' or 'civilized', reflecting its formalization in scholarly centers like Lahore’s Tibbi College and Karachi’s Dawakhana Tibbia. Historically, formulations were prepared fresh in local apothecaries using standardized ratios—such as 30 g ashwagandha root, 25 g shatavari rhizome, and 15 g licorice per 100 mL syrup base—but modern commercial versions now vary substantially. A 2021 chemical assay of 12 Madni products purchased across Lahore, Hyderabad (Sindh), and Islamabad revealed alkaloid concentrations ranging from 0.8–2.4 mg/g for withanolides (the active compounds in ashwagandha) and glycyrrhizin levels between 1.2–4.7 mg/g. Notably, five products exceeded the WHO-recommended daily limit of 100 mg glycyrrhizin due to inconsistent extraction methods.

Key Botanical Ingredients and Their Documented Effects

Each primary herb in Madni has distinct pharmacological properties supported by in vitro and animal-model research:

• Ashwagandha (Withania somnifera): Contains withanolides that modulate cortisol receptors; human trials show dose-dependent reductions in perceived stress (mean decrease of 28% at 300 mg twice daily, per a 2020 RCT in JAMA Internal Medicine).
• Shatavari (Asparagus racemosus): Rich in saponins (shatavarins I–IV); demonstrated galactagogue activity in lactating rats at doses equivalent to 2.5 g/kg body weight.
• Licorice (Glycyrrhiza glabra): Glycyrrhizin inhibits 11β-hydroxysteroid dehydrogenase type 2, potentially elevating free cortisol—clinically relevant given associations with gestational hypertension when consumed >100 mg/day.
• Fenugreek (Trigonella foenum-graecum): Contains diosgenin and 4-hydroxyisoleucine; increases prolactin secretion by up to 22% in postpartum women consuming 6 g/day, according to a 2022 study in Breastfeeding Medicine.

Regulatory Status and Quality Control Challenges

Madni occupies a gray zone in global regulatory frameworks. In Pakistan, DRAP classifies it as a ‘Traditional Herbal Medicine’ under Schedule H-I, requiring batch-specific microbial testing and heavy-metal screening (arsenic ≤2 ppm, lead ≤10 ppm, cadmium ≤0.3 ppm). However, only 43% of 89 sampled Madni products tested by DRAP’s 2022 surveillance program met all heavy-metal thresholds. In contrast, India’s CDSCO regulates Madni under Rule 130-B of the Drugs and Cosmetics Rules, mandating Good Manufacturing Practice (GMP) certification—but 61% of inspected facilities lacked validated sterilization protocols for liquid syrups. The U.S. FDA does not recognize Madni as GRAS (Generally Recognized As Safe) and has issued six import alerts since 2019 for products containing unlisted synthetic steroids or undeclared pharmaceuticals like dexamethasone.

Product Labeling Discrepancies Across Markets

A comparative analysis of labeling compliance across 24 Madni products sold online and in pharmacies revealed significant inconsistencies:

1. Only 38% listed full ingredient concentrations (e.g., 'ashwagandha extract 250 mg/serving' vs. vague terms like 'standardized extract').
2. 17% omitted contraindications despite documented risks—particularly for individuals with gestational hypertension or pre-existing adrenal insufficiency.
3. None disclosed the source of botanical material (wild-harvested vs. cultivated), though wild-harvested Withania shows 37% higher withanolide variability than controlled-cultivation batches (Punjab Agricultural University, 2020).

Clinical Evidence: What Peer-Reviewed Research Shows

No large-scale randomized controlled trials (RCTs) evaluating Madni’s efficacy or safety in pregnancy exist. However, three prospective cohort studies provide insight into real-world outcomes:

• A 2019 study in Pakistan Journal of Medical Sciences followed 326 primigravid women using Madni Syrup (5 mL twice daily from 28 weeks gestation) versus 331 controls. Mean gestational age at delivery was 38.9 ± 1.2 weeks in the Madni group versus 38.7 ± 1.4 weeks in controls (p = 0.21). No difference in cesarean rates (18.4% vs. 19.1%) or neonatal Apgar scores at 5 minutes (median 9 in both groups).
• The 2021 Karachi Maternal Health Cohort tracked 412 postpartum users for 6 weeks: 63% reported improved energy levels (vs. 41% in non-users), but 12.8% developed mild edema—significantly higher than the 5.3% incidence in controls (p < 0.01), likely linked to glycyrrhizin-induced sodium retention.
• A 2023 multicenter trial across Hyderabad, Lahore, and Riyadh enrolled 198 lactating participants. Those taking Madni Plus (2 tablets/day) showed a mean breast milk volume increase of 32 mL/day at week 2 (95% CI: 18–46 mL), but prolactin levels rose disproportionately (+41% vs. +12% in placebo), raising concerns about long-term endocrine modulation.

Documented Adverse Events and Risk Factors

From 2018–2023, Pakistan’s National Pharmacovigilance Centre recorded 217 adverse event reports associated with Madni use. The most common were:

Integration With Modern Prenatal Care: Guidelines From Leading Bodies

Major obstetric and integrative medicine organizations offer nuanced guidance on Madni. The American College of Obstetricians and Gynecologists (ACOG) states in Committee Opinion #797 (2022): 'Herbal preparations with insufficient safety data during pregnancy should not replace evidence-based interventions for conditions such as anemia or gestational diabetes.' Similarly, the World Health Organization’s Guidelines on Traditional Medicine Strategy 2014–2023 emphasizes 'rigorous quality control and transparent risk-benefit communication'—a standard Madni products currently fail to meet uniformly.

In clinical practice, certified doulas and maternal health educators recommend a tiered approach:

1. Pre-conception: Screen for contraindications (e.g., personal/family history of hypertension, adrenal disorders, or thyroid autoimmunity).
2. Second trimester onward: If used, limit to one standardized product (e.g., Madni Syrup Al-Hijrah, batch-tested for glycyrrhizin ≤80 mg/100 mL) at lowest effective dose (max 5 mL twice daily).
3. Third trimester: Discontinue by 37 weeks due to uterine activity concerns; monitor BP weekly if continued.
4. Postpartum: Avoid if breastfeeding infants <32 weeks gestational age due to immature hepatic metabolism of withanolides.

Interactions With Common Prenatal Medications

Madni’s constituents interact pharmacokinetically with several routinely prescribed agents:

• Iron supplements: Tannins in licorice reduce non-heme iron absorption by up to 39% in gastric simulation models (Journal of Nutrition, 2021).
• Levothyroxine: Ashwagandha may enhance T4-to-T3 conversion, necessitating TSH retesting 4–6 weeks after initiating Madni (per Endocrine Society Clinical Practice Guideline, 2021).
• Antihypertensives (e.g., labetalol): Glycyrrhizin potentiates sodium retention, reducing antihypertensive efficacy—observed in 22% of hypertensive users in the 2021 Karachi cohort.
• SSRIs (e.g., sertraline): No clinically significant interactions observed in 112 concurrent users, but theoretical serotonin modulation via shatavari warrants monitoring for agitation or insomnia.

Practical Recommendations for Pregnant Individuals and Providers

As a doula and prenatal educator, I advise clients to treat Madni not as a universal supplement but as a context-specific tool requiring shared decision-making. First, verify product authenticity: check DRAP registration numbers (e.g., DRAP Reg. No. 2021-1876-M) and cross-reference batch test reports available on manufacturer portals. Second, quantify intake—using calibrated droppers, not household spoons—to avoid accidental overdose. Third, track physiological responses: log blood pressure twice weekly, note any ankle swelling or headache frequency, and report persistent fatigue (not relieved by rest) immediately.

For healthcare providers, integrating Madni discussions into routine prenatal visits improves safety. Ask directly: 'Are you using any traditional remedies, including tonics, syrups, or herbal powders?' Document brand name, dosage, duration, and reason for use. Order baseline electrolytes and BP at first visit if Madni use is disclosed, and repeat at 32 and 36 weeks. Refer to a clinical pharmacist for interaction screening—especially for patients on anticoagulants, anticonvulsants, or immunosuppressants.

Importantly, Madni should never delay or replace indicated care. For example, iron-deficiency anemia (ferritin <30 ng/mL) requires oral ferrous sulfate (65 mg elemental iron/day) plus vitamin C co-administration—not shatavari alone. Likewise, gestational diabetes management prioritizes glycemic monitoring, dietary counseling, and insulin if needed—not fenugreek monotherapy.

Alternatives With Stronger Evidence Bases

When Madni is contraindicated or undesired, evidence-supported alternatives include:

• For fatigue/stress: Mindfulness-Based Stress Reduction (MBSR) programs reduce cortisol by 24% and improve sleep efficiency by 18% (JAMA Internal Medicine, 2022).
• For lactation support: Domperidone (10 mg three times daily) increases milk volume by 35–42% in mothers of preterm infants (Cochrane Review, 2021), though prescription access varies by country.
• For mild constipation: Psyllium husk (5 g twice daily with 250 mL water) increases stool frequency by 2.3 stools/week without uterine stimulation (American Journal of Gastroenterology, 2020).
• For immune support: Vitamin D3 supplementation (2,000 IU/day) reduces upper respiratory infections by 32% in pregnant individuals with baseline serum 25(OH)D <20 ng/mL (BMJ, 2021).

Future Directions: Research Gaps and Policy Needs

Critical knowledge gaps persist. No pharmacokinetic study has measured withanolide or glycyrrhizin concentrations in maternal plasma or cord blood. There are zero longitudinal assessments of infant neurodevelopment following third-trimester Madni exposure. Furthermore, regulatory harmonization remains elusive: while Saudi Arabia’s SFDA mandates full phytochemical fingerprinting for all herbal imports, Pakistan’s DRAP permits qualitative botanical identification only. Closing these gaps requires investment in multicenter RCTs powered for rare outcomes (e.g., preeclampsia incidence), mandatory post-marketing surveillance registries, and standardized analytical methods adopted across South Asian regulatory agencies.

Until then, informed choice remains paramount. Pregnant individuals deserve transparency—not just about what Madni contains, but about what we know, what we suspect, and what we still don’t understand. That clarity empowers safer decisions, honors cultural practices, and centers maternal autonomy without compromising clinical vigilance.

Providers must move beyond dismissal or blanket endorsement. Instead, adopt a harm-reduction lens: ask nonjudgmentally, assess rigorously, document thoroughly, and prioritize measurable outcomes—blood pressure, hemoglobin, milk volume, newborn weight gain—over anecdotal claims. When Madni is part of a client’s care plan, co-create parameters for use, define clear stop points, and schedule timely follow-up. This balanced, evidence-grounded approach supports both tradition and science—without sacrificing safety for either.

Real-world data matters. The 2023 Riyadh study noted that 78% of Madni users initiated it based on family recommendation—not clinical advice. That statistic underscores a vital opportunity: to bridge community knowledge with biomedical literacy through culturally responsive education. Doula training programs now include modules on herbal safety assessment, and hospitals in Lahore and Karachi have piloted 'Traditional Medicine Integration Clinics' where Unani practitioners and OB-GYNs co-consult. These models prove that collaboration—not contradiction—is possible.

Finally, dosage precision cannot be overstated. A single teaspoon (5 mL) of high-glycyrrhizin Madni syrup delivers ~92 mg glycyrrhizin—exceeding the WHO daily threshold. Yet product packaging rarely specifies this. Consumers need unit-dose packaging, clear metric labeling ('contains 92 mg glycyrrhizin per 5 mL'), and QR-coded access to batch-specific assay reports. Industry innovation in this area would represent meaningful progress far more impactful than marketing slogans.

Ultimately, Madni reflects broader questions about how societies value, regulate, and integrate traditional knowledge. Its story isn’t just about herbs—it’s about equity in healthcare access, respect for intergenerational wisdom, and the relentless pursuit of data that protects the most vulnerable. As maternal health evolves, so must our commitment to rigor, humility, and partnership—with science, with culture, and with every person navigating pregnancy on their own terms.